A multisource adalimumab tender run by England’s National Health Service (NHS) on a regional basis late last year was a marked improvement over previous procurement practices for biosimilars, according to Warwick Smith, director general of the British Biosimilars Association (BBA). But it could have been better, he told delegates to Medicines for Europe’s biosimilar medicines conference held in Amsterdam, the Netherlands.
Admitting a degree of surprise at how the industry’s arguments around sustainability had been reflected in the adalimumab tender, Smith...
